Download PDF
Geburtshilfe Frauenheilkd 2005; 65(1): 23-29
DOI: 10.1055/s-2004-830402
Übersicht

Georg Thieme Verlag KG Stuttgart · New York

Der Einsatz von Tissue Microarrays (TMA) - eine neue Technik in der gynäkologischen Tumorforschung

Tissue Microarrays - Application and Limitations in Gynecologic Oncology ResearchL.-C. Horn1 , S. Faber2 , J. Einenkel2 , C. B. Gilks3 , C. E. Richter1 , 2 , H. Stepan2 , S. Purz2 , C. Krumpe1 , C. Leo2
  • 1Institut für Pathologie, Abteilung für Gynäkopathologie, Universität Leipzig
  • 2Universitäts-Frauenklinik Leipzig (Triersches Institut), Leipzig
  • 3Genetic Pathology Evaluation Centre of the Department of Pathology and Prostate Research Centre, Vancouver General Hospital, British Columbia Cancer Agency and University of British Columbia, Vancouver, BC, Canada
Further Information

Publication History

Eingang Manuskript: 26. Mai 2004 Eingang revidiertes Manuskript: 3. September 2004

Akzeptiert: 9. September 2004

Publication Date:
29 November 2004 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Multigewebeblöcke, so genannte tissue microarrays (TMA), sind eine neue Technik für die molekulare Charakterisierung von Tumoren auf der Ebene der Proteine (Proteomics), Zucker (Glycomics) und DNA mittels verschiedener In-situ-Techniken (Immunhistochemie, FISH, tunel-Assay u. a.). Die Erstellung der TMAs erfolgt rein mechanisch. Aus konventionellen Paraffinblöcken von verschiedenen klinikopathologisch charakterisierten Tumoren (sog. Donorblöcke) werden mittels eines kommerziell erhältlichen Gerätes (sog. Arrayer) Gewebezylinder entnommen und in einen neu zu erstellenden Paraffinblock (Rezipientblock = TMA-Block) nach einem präzisen Schema eingebracht. Das Problem der intratumoralen Heterogenität ist durch die Verwendung von 2 - 3 Zylindern pro Tumor zu vernachlässigen. Vom TMA-Block können dann multiple Schnitte mit einem Mikrotom angefertigt werden, die dann für die Analyse von pathogenetisch relevanten, prädiktiven und prognostischen Faktoren zur Verfügung stehen. Die TMAs sind besonders geeignet im Rahmen der Evaluierung von Parametern prospektiver Studien in Bezug auf das Therapieansprechen („translational research“). Die Vorteile der Anwendung von TMAs in der gynäkologischen Tumorforschung überwiegen deutlich deren Nachteile. TMAs stellen somit eine wertvolle neue Methode für die klinische Forschung dar.

Abstract

The use of tissue microarrays (TMAs) is a new technique in molecular profiling of tumors using immunohistochemistry as well as molecular hybridisation techniques. It represents a mechanical technique which involves taking 0.6 to 2.0 mm tissue cores from multiple (donor) blocks of well characterised tumors with subsequent precise insertion (arraying) into empty (recipient) blocks - the TMA block. This block can be essentially processed as a regular paraffin block with nearly the same advantages and disadvantages. The problem of tumor heterogeneity is solved by including 2 - 3 cores from each tumor into the TMA block. Thus this technique offers significantly faster and cheaper evaluation of a large number (up to several hundreds of samples per TMA block) of tumors and provide an easy access to material for further studies using stored TMA blocks. TMAs will provide a valuable new tool for translational research, especially in the evaluation of predictive parameters in prospective multi-centre studies.

Schlüsselwörter

Gewebe Mikroarray - Immunhistochemie - Molekularbiologie - Tumor - gynäkologische Onkologie

Key words

Tissue microarray - in situ techniques - immunohistochemistry - molecular profiling - molecular biology - tumor

Literatur

  • 1 Al-Kushi A, Irving J, Hsu F, Dupuis B, Liu C L, van de Rijn M, Gilks C B. Immunoprofile of cervical and endometrial adenocarcinomas using tissue microarray.  Virchows Arch. 2003;  44 271-277
    PubMedGoogle Scholar
  • 2 Bartlett J, Mallon E, Cooke T. The clinical evaluation of HER2 status: Which test to use?.  J Pathol. 2003;  199 411-417
    PubMedGoogle Scholar
  • 3 Battifora H. The multitumor (saussage) tissue block: Novel method for immunohistochemical antibody testing.  Lab Invest. 1986;  55 244-248
    PubMedGoogle Scholar
  • 4 Bova G S, Parmigiani G, Epstein J I, Wheeler T, Mucci N R, Rubin M A. Web-based tissue microarray image data analysis: Initial validation testing through prostate cancer Gleason grading.  Hum Pathol. 2001;  32 417-427
    CrossrefPubMedGoogle Scholar
  • 5 Bubendorf L, Nocito A, Moch H, Sauter G. Tissue microarray (TMA) technology: Miniaturized pathology archives for high-throughput in in situ studies.  J Pathol. 2001;  195 72-79
    PubMedGoogle Scholar
  • 6 Camp R L, Charette L A, Rimm D L. Validation of tissue microarray technology in breast carcinoma.  Lab Invest. 2000;  80 1943-1949
    PubMedGoogle Scholar
  • 7 Chen Y, Miller C, Mosher R, Zaho X, Deeds J, Morrissey M, Bryant B, Yang D, Meyer R, Cronin F, Gostout B S, Smith-McCune K, Schlegel R. Identification of cervical cancer markers by cDNA and tissue microarrays.  Cancer Res. 2003;  63 1927-1935
    PubMedGoogle Scholar
  • 8 Cheng Q, Lau W M, Tay S K, Chew S H, Ho T H, Hui K M. Identification and characterisation of genes involved in the carcinogenesis of human squamous cell cervical carcinoma.  Int J Cancer. 2002;  20 419-426
    PubMedGoogle Scholar
  • 9 Emmert-Buck M R, Strausberg R L, Krizman D B, Bonaldo M F, Bonner R F, Bostwick D G, Bromwn M R, Buetow K H, Chuaqui R F, Cole K A, Duray P H, Englert C R, Gillespie J W, Greenhut S, Grouse L, Hillier L W, Katz K S, Klausner R D, Kuznetzov V, Lash A E, Lennon G, Linehan W M, Liotta L A, Marra M A, Musnson P J, Omstein D K, Prabhu V V, Prange C, Schuler G D, Soares M B, Tolstoshev C M, Vocke C D, Waterson R H. Molecular profiling of clinical tumor specimens. Feasibility and applications.  Am J Pathol. 2000;  156 1109-1115
    PubMedGoogle Scholar
  • 10 Gillett C E, Springall R J, Barnes D M, Hanby A M. Multiple tissue core arrays in histopathology research: A validation study.  J Pathol. 2000;  192 549-553
    PubMedGoogle Scholar
  • 11 Gulman C, O'Grady A. Tissue microarrays: An overview.  Curr Diagn Pathol. 2003;  9 149-154
    PubMedGoogle Scholar
  • 12 Hedvat C V, Hedge A, Changanti R SK, Chen B, Quin J, Filipa D A, Nimer S D, Teruya-Feldstein J. Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma.  Hum Pathol. 2002;  33 968-974
    CrossrefPubMedGoogle Scholar
  • 13 Hidalgo A, Pina P, Guerrero G, Lazos M, Salcedo M. A simple method for the construction of small format tissue arrays.  J Clin Pathol. 2003;  56 144-146
    CrossrefPubMedGoogle Scholar
  • 14 Hoos A, Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell lines: Opportunities and limitations.  Lab Invest. 2001;  81 1331-1338
    PubMedGoogle Scholar
  • 15 Hoos A, Urist M J, Stojadinovic A, Mastorides S, Dudas M E, Leung D H, Kuo D, Brennan M F, Lewis J J, Cordon-Cardo C. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors.  Am J Pathol. 2001;  158 1245-1251
    PubMedGoogle Scholar
  • 16 Horn L C, Bilek K. The usefulness of tumor registry in cervical cancer.  Zentralbl Gynakol. 2001;  123 311-314
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Horn L C, Fischer U, Hänel C, Kuhn H, Raptis G, Bilek K. p53 in surgically treated and pathologically staged cervical cancer: Correlation with local tumor progression, but not with lymphatic spread.  Path Res Pract. 2001;  197 605-609
    PubMedGoogle Scholar
  • 18 Kang J Y, Dolled-Filhart M, Ocal I T, Singh B, Lin C Y, Dockson R B, Rimm D L, Camp R L. Tissue microarray analysis of hepatocytic growth factor/Met pathway components reveals a role for MET, matriptase and hepatocyte growth factor inhibitor 1 in the progression of node-negative breast cancer.  Cancer Res. 2003;  63 1101-1105
    PubMedGoogle Scholar
  • 19 Kaulen H. Für eine bessere Gesundheitsforschung: Biobanken.  DMW. 2003;  123 2629-2630
    PubMedGoogle Scholar
  • 20 Kim M H, Seo S S, Song X S, Kang D H, Park I A, Kang K B, Lee H P. Expression of cyclooxygenase-1 and - 2 associated with expression of VEGF in primary cervical cancer and at metastatic lymph nodes.  Gynecol Oncol. 2003;  90 83-90
    CrossrefPubMedGoogle Scholar
  • 21 Kononen J, Bubendorf L, Kalloniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch M J, Sauter G, Kalloniemi O P. Tissue microarrays for high-throughput molecular profiling of tumor specimens.  Nature Med. 1998;  4 844-847
    PubMedGoogle Scholar
  • 22 Moch H, Kononen J, Kallioniemi O P, Sauter G. Tissue microarrays: What they will bring to molecular and anatomic pathology?.  Adv Anat Pathol. 2001;  8 14-20
    PubMedGoogle Scholar
  • 23 Nitz G, Dierks C. Nochmals: Forschung an und mit Körpersubstanzen - wann ist die Einwilligung des ehemaligen Trägers erforderlich?.  MedR. 2002;  8 400-403
    PubMedGoogle Scholar
  • 24 Nocito A, Kononen J, Kalloniemi O P, Sauter G. Tissue microarrays (TMAs) for high-throughput pathology research.  Int J Cancer. 2001;  94 1-5
    CrossrefPubMedGoogle Scholar
  • 25 Ouban A, Muraca P, Yeatman T, Coppola D. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas.  Hum Pathol. 2003;  34 803-808
    CrossrefPubMedGoogle Scholar
  • 26 Reis-Filho J S, Simpson P T, Martins A, Preto A, Gartner F, Schnitt F C. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray.  Virchows Arch. 2003;  443 122-132
    CrossrefPubMedGoogle Scholar
  • 27 Rubin M A, Dunn R, Strawderman M, Pienta K J. Tissue microarray sampling strategy for prostate cancer biomarker analysis.  Am J Surg Pathol. 2002;  26 312-319
    CrossrefPubMedGoogle Scholar
  • 28 Schraml P, Bucher C, Bissig H, Nocito A, Haas P, Wilber K, Seelig S, Kononen J, Mihatsch M J, Dirnhofer S, Sauter G. Cyclin E overexpression and amplification in human tumors.  J Pathol. 2003;  200 375-382
    PubMedGoogle Scholar
  • 29 Schraml P, Kononen J, Bubendorf L, Bissig H, Nocito A, Mihatsch M J, Kallioniemi O P, Sauter G. Tissue microarrays for gene amplification surveys in many different tumor types.  Clin Cancer Res. 1999;  5 1966-1975
    PubMedGoogle Scholar
  • 30 Simon R, Mirlacher M, Sauter G. Tissue microarrays in cancer diagnosis.  Expert Rev Mol Diagn. 2003;  3 421-430
    CrossrefPubMedGoogle Scholar
  • 31 Tolgay Ocal, Dolled-Filhart M, D'Aquila T G, Camp R L, Rimm D L. Tissue-microarray-based studies of patients with lymph node negative breast carcinoma show that met-expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.  Cancer. 2003;  97 1841-1848
    CrossrefPubMedGoogle Scholar
  • 32 Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Köchli O R, Mross F, Dieterich H, Moch H, Mihatsch M J, Kalloniemi O P, Sauter G. Tissue microarrays for rapid linking of molecular changes to clinical endpoints.  Am J Pathol. 2001;  153 2249-2256
    PubMedGoogle Scholar
  • 33 Van de Rijn M, Perou C M, Tibshirani R, Haas P, Kallionemi O P, Kononen J, Torhorst J, Sauter G, Zuber M, Köchli O R, Mross, Dieterich H, Seitz R, Ross D, Botestein D, Brown P. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome.  Am J Pathol. 2002;  161 1991-1996
    PubMedGoogle Scholar
  • 34 Van den Rijn M, Gilks C B. Applications of microarrays to histopathology.  Histopathology. 2004;  44 97-108
    CrossrefPubMedGoogle Scholar

Prof. Dr. med. Lars-Christian Horn

Institut für Pathologie
Universität Leipzig

Liebigstraße 26

04103 Leipzig

Email: hornl@medizin.uni-leipzig.de

      >